Zolgensma – Gene Therapy for Spinal Muscular Atrophy
Zolgensma is a gene therapy for the treatment of spinal muscular atrophy (SMA) in young children. It is a one-time infusion that replaces the defective SMN1 gene.
Things worth knowing about "Zolgensma"
Zolgensma is a gene therapy for the treatment of spinal muscular atrophy (SMA) in young children. It is a one-time infusion that replaces the defective SMN1 gene.
What is Zolgensma?
Zolgensma (active substance: onasemnogene abeparvovec) is a gene therapy medicinal product used to treat spinal muscular atrophy (SMA). It is administered as a single intravenous infusion designed to replace the missing or defective SMN1 gene (Survival Motor Neuron 1) with a functional copy. Developed by Novartis Gene Therapies, Zolgensma is approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
Indication
Zolgensma is approved for patients with:
- SMA Type 1 (the most severe form of SMA)
- Patients with up to 3 copies of the SMN2 gene, regardless of clinical presentation
- Body weight up to 21 kg
Treatment should be initiated as early as possible, ideally within the first months of life, as the therapy is most effective when administered before significant motor neuron loss has occurred.
Mechanism of Action
Zolgensma uses a modified adeno-associated virus serotype 9 (AAV9) as a vector to deliver a functional copy of the human SMN1 gene directly into the motor neurons of the spinal cord. The SMN protein (Survival Motor Neuron) is essential for the survival and proper function of motor neurons. In patients with SMA, this protein is absent or severely reduced due to mutations in the SMN1 gene, leading to progressive motor neuron loss and muscle weakness. A single dose of Zolgensma permanently supplements the defective gene, restoring SMN protein production.
Dosage and Administration
Zolgensma is administered as a single one-time intravenous infusion. The recommended dose is 1.1 × 1014 vector genomes per kilogram of body weight (vg/kg). The infusion takes place in a specialized medical center under inpatient conditions. Patients receive corticosteroids before and after the infusion to reduce the risk of liver inflammation (hepatotoxicity).
Side Effects
Zolgensma can cause serious side effects. The most clinically significant include:
- Elevated liver enzymes (hepatotoxicity) – requiring regular liver function monitoring
- Thrombotic microangiopathy (TMA) – a serious condition affecting small blood vessels
- Immune reactions to the AAV9 viral vector
- Elevated troponin levels indicating potential cardiac stress
- Fever, vomiting, and behavioral changes associated with the infusion
Due to these risks, close medical supervision before, during, and after treatment is essential.
Clinical Context and Significance
Zolgensma is widely regarded as one of the most groundbreaking advances in the history of gene therapy. Clinical trials, particularly the START and STR1VE studies, demonstrated that children treated with Zolgensma achieved motor milestones such as sitting independently, and in some cases standing and walking – outcomes that are typically unachievable in untreated SMA Type 1 patients. With a list price exceeding two million US dollars, Zolgensma is one of the most expensive medications in the world. Reimbursement is regulated through health insurance systems and national healthcare authorities in many countries.
References
- European Medicines Agency (EMA): Zolgensma (onasemnogene abeparvovec) – Product Information and EPAR. Available at: https://www.ema.europa.eu
- Mendell JR et al. (2017): Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. New England Journal of Medicine, 377(18):1713–1722.
- Day JW et al. (2021): Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. The Lancet Neurology, 20(4):284–293.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryEpicondylitis
Spondylolisthesis
Chondromalacia
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Zolgensma